ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC

Excerpt from the Press Release:

FREMONT, CA, June 16, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the submission of its Vitrargus Phase II study to the Australian Bellberry Human Research Ethics Committee (HREC). If received, HREC approval will lead to a Clinical Trial Notification (CTN) submission to the Australian Therapeutic Goods Administration (TGA) for review, which is the final regulatory step before study initiation.

Early clinical studies indicate that Vitargus has unique properties that result in eliminating the need for post-surgery patient face-down positioning, as well as significantly greater patient comfort and visual acuity during the surgical recovery period than currently available products. The objective of the Phase II study, titled “A Perspective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of ABV-1701 Ocular Endotamponade (OE),” is to demonstrate the safety and effectiveness of Vitargus when compared to the commonly used SF6 Gas OE.

“The Phase II study is targeted to begin in August of 2022 in both Australia and Thailand and is expected to be completed by the end of 2023,” said Dr. Howard Doong, Chief Executive Officer of the ABVC. According to iHealthcareAnalyst, Inc., the global market for retinal surgery devices is expected to reach $3.7 billion by 2027, driven by a rising geriatric population worldwide.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development.

Click the button below to read the entire Press Release:

Continue Reading The Press Release